• Je něco špatně v tomto záznamu ?

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

MA Dimopoulos, MV Mateos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, M Kropff, I Spicka, A Palumbo, KL Wu, DL Esseltine, K Liu, W Deraedt, A Cakana, De Velde H Van, Miguel JF San

. 2011 ; 86 (1) : 23-31.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17015128

Grantová podpora
NT12215 MZ0 CEP - Centrální evidence projektů

OBJECTIVES: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone. METHODS: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m(2), days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, and days 1, 8, 22, 29, cycles 5-9; melphalan 9 mg/m(2), days 1-4, cycles 1-9; and prednisone 60 mg/m(2), days 1-4, cycles 1-9). RESULTS: Overall, 47% of patients receiving VMP developed PN, including 19% grade 2 and 13% grade > 3 (<1% grade 4). The PN incidence was dose-related and reached a plateau at a cumulative bortezomib dose of approximately 45 mg/m(2). Median time to PN onset was 2.3 months. Bortezomib-associated PN was reversible; 79% of events improved by at least one NCI CTCAE grade within a median of 1.9 months and 60% completely resolved within a median of 5.7 months, with reversibility similar in responding and non-responding patients. By multivariate analysis, baseline neuropathy was the only consistent risk factor for any PN [hazard ratio (HR) 1.785, P=0.0065], grade > 2 PN (HR 2.205, P=0.0032), and grade > 3 PN (HR 2.438, P=0.023); age, pre-existing diabetes, International Staging System stage, obesity, and creatinine clearance did not affect the overall rate of PN. CONCLUSIONS: Rates of bortezomib-induced PN in the frontline setting were similar to those in relapsed patients and resolved in most cases. Copyright © 2010 John Wiley & Sons A/S.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17015128
003      
CZ-PrNML
005      
20190104104454.0
007      
ta
008      
170425s2011 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1600-0609.2010.01533.x $2 doi
035    __
$a (PubMed)20874823
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dimopoulos MA $u Dimopoulos, Meletios A. School of Medicine, University of Athens, Athens, Greece. mdimop@med.uoa.gr
245    10
$a Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study / $c MA Dimopoulos, MV Mateos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, M Kropff, I Spicka, A Palumbo, KL Wu, DL Esseltine, K Liu, W Deraedt, A Cakana, De Velde H Van, Miguel JF San
520    9_
$a OBJECTIVES: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone. METHODS: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m(2), days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, and days 1, 8, 22, 29, cycles 5-9; melphalan 9 mg/m(2), days 1-4, cycles 1-9; and prednisone 60 mg/m(2), days 1-4, cycles 1-9). RESULTS: Overall, 47% of patients receiving VMP developed PN, including 19% grade 2 and 13% grade > 3 (<1% grade 4). The PN incidence was dose-related and reached a plateau at a cumulative bortezomib dose of approximately 45 mg/m(2). Median time to PN onset was 2.3 months. Bortezomib-associated PN was reversible; 79% of events improved by at least one NCI CTCAE grade within a median of 1.9 months and 60% completely resolved within a median of 5.7 months, with reversibility similar in responding and non-responding patients. By multivariate analysis, baseline neuropathy was the only consistent risk factor for any PN [hazard ratio (HR) 1.785, P=0.0065], grade > 2 PN (HR 2.205, P=0.0032), and grade > 3 PN (HR 2.438, P=0.023); age, pre-existing diabetes, International Staging System stage, obesity, and creatinine clearance did not affect the overall rate of PN. CONCLUSIONS: Rates of bortezomib-induced PN in the frontline setting were similar to those in relapsed patients and resolved in most cases. Copyright &#xa9; 2010 John Wiley & Sons A/S.
590    __
$a bohemika - dle Pubmed
650    02
$a senioři $7 D000368
650    02
$a senioři nad 80 let $7 D000369
650    12
$a protokoly antitumorózní kombinované chemoterapie $7 D000971
650    02
$a kyseliny boronové $x aplikace a dávkování $7 D001897
650    12
$a kyseliny boronové $x toxicita $7 D001897
650    02
$a bortezomib $7 D000069286
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a mužské pohlaví $7 D008297
650    02
$a melfalan $x aplikace a dávkování $x škodlivé účinky $7 D008558
650    02
$a lidé středního věku $7 D008875
650    12
$a mnohočetný myelom $x farmakoterapie $x komplikace $7 D009101
650    02
$a multivariační analýza $7 D015999
650    12
$a nemoci periferního nervového systému $x etiologie $x chemicky indukované $7 D010523
650    02
$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241
650    02
$a Pyrazines $x ad [Administration & Dosage]
650    12
$a pyraziny $x toxicita $7 D011719
650    02
$a rizikové faktory $7 D012307
700    1_
$a Mateos MV
700    1_
$a Richardson PG
700    1_
$a Schlag R
700    1_
$a Khuageva NK
700    1_
$a Shpilberg O
700    1_
$a Kropff M
700    1_
$a Špička, Ivan, $d 1960- $7 jn20001103644
700    1_
$a Palumbo A
700    1_
$a Wu KL
700    1_
$a Esseltine DL
700    1_
$a Liu K
700    1_
$a Deraedt W
700    1_
$a Cakana A
700    1_
$a Van De Velde H
700    1_
$a San Miguel JF
773    0_
$t European Journal of Haematology $g Roč. 86, č. 1 (2011), s. 23-31 $p Eur J Haematol $x 0902-4441 $w MED00001620
773    0_
$p Eur J Haematol $g 86(1):23-31, 2011 Jan
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20170425153427 $b ABA008
991    __
$a 20190104104650 $b ABA008
999    __
$a ok $b bmc $g 1202104 $s 975912
BAS    __
$a 3
BMC    __
$a 2011 $b 86 $c 1 $d 23-31 $x MED00001620 $i 0902-4441 $m European journal of haematology
GRA    __
$a NT12215 $p MZ0
LZP    __
$a NLK 2015-B/lp

Najít záznam

Citační ukazatele

Možnosti archivace